On October 4, 2024, Humacyte, Inc. announced the pricing of a registered direct offering, entering into a securities purchase agreement with an institutional investor. The offering involves the sale of approximately $30.0 million worth of its common stock and warrants.
Under the terms, Humacyte agreed to sell 5,681,820 shares of common stock and warrants to purchase an equal number of shares. The purchase price for one share of common stock and one warrant is $5.28.
The gross proceeds from this offering are estimated to be approximately $30.0 million, before deducting fees and expenses. The offering is expected to close around October 7, 2024, providing capital for the company's operations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.